Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiess⃞s⃞ The online version of this article (available at http://www.jlr.org) contains additional text, figures, and references. Published, JLR Papers in Press, March 16, 2005. DOI 10.1194/jlr.M

The paraoxonase (PON) gene family in humans has three members, PON1, PON2, and PON3. Their physiological role(s) and natural substrates are uncertain. We developed a baculovirus-mediated expression system, suitable for all three human PONs, and optimized procedures for their purification. The recombinant PONs are glycosylated with high-mannose-type sugars, which are important for protein stability but are not essential for their enzymatic activities. Enzymatic characterization of the purified PONs has revealed them to be lactonases/lactonizing enzymes, with some overlapping substrates (e.g., aromatic lactones), but also to have distinctive substrate specificities. All three PONs metabolized very efficiently 5-hydroxy-eicosatetraenoic acid 1,5-lactone and 4-hydroxy-docosahexaenoic acid, which are products of both enzymatic and nonenzymatic oxidation of arachidonic acid and docosahexaenoic acid, respectively, and may represent the PONs' endogenous substrates. Organophosphates are hydrolyzed almost exclusively by PON1, whereas bulky drug substrates such as lovastatin and spironolactone are hydrolyzed only by PON3. Of special interest is the ability of the human PONs, especially PON2, to hydrolyze and thereby inactivate N-acyl-homoserine lactones, which are quorum-sensing signals of pathogenic bacteria. None of the recombinant PONs protected low density lipoprotein against copper-induced oxidation in vitro.

[1]  A. Dugrillon.  Iodolactones and iodoaldehydes — mediators of iodine in thyroid autoregulation , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  P. Connelly,et al.  Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite. , 2005, Free radical biology & medicine.

[3]  D. Pritchard,et al.  Differential Immune Modulatory Activity of Pseudomonas aeruginosa Quorum-Sensing Signal Molecules , 2004, Infection and Immunity.

[4]  D. Spring,et al.  Communications blackout? Do N-acylhomoserine-lactone-degrading enzymes have any role in quorum sensing? , 2004, Microbiology.

[5]  Dan S. Tawfik,et al.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes , 2004, Nature Structural &Molecular Biology.

[6]  C. Godson,et al.  Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. , 2004, Kidney international.

[7]  C. Serhan,et al.  Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. , 2004, Prostaglandins & other lipid mediators.

[8]  E. Greenberg,et al.  Inactivation of a Pseudomonas aeruginosa quorum-sensing signal by human airway epithelia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Jarvik,et al.  Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. , 2003, Annual review of medicine.

[10]  Antonio F. Hernández,et al.  Identification of paraoxonase 3 in rat liver microsomes: purification and biochemical properties. , 2003, The Biochemical journal.

[11]  T. Standiford,et al.  The Pseudomonas aeruginosa Autoinducer N-3-Oxododecanoyl Homoserine Lactone Accelerates Apoptosis in Macrophages and Neutrophils , 2003, Infection and Immunity.

[12]  R. Kingston.  Introduction of DNA into Mammalian Cells , 2003 .

[13]  B. La Du,et al.  Lactonase and lactonizing activities of human serum paraoxonase (PON1) and rabbit serum PON3. , 2003, Biochemical pharmacology.

[14]  C. Watson,et al.  Mouse Macrophage Paraoxonase 2 Activity Is Increased Whereas Cellular Paraoxonase 3 Activity Is Decreased Under Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[15]  G. Zimmerman,et al.  Platelet-activating Factor Acetylhydrolase, and Not Paraoxonase-1, Is the Oxidized Phospholipid Hydrolase of High Density Lipoprotein Particles* , 2003, The Journal of Biological Chemistry.

[16]  A. Emili,et al.  Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. , 2002, Biochemical and biophysical research communications.

[17]  S. Reddy,et al.  Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein* , 2001, The Journal of Biological Chemistry.

[18]  T. Forte,et al.  Baculovirus-mediated expression and purification of human serum paraoxonase 1A. , 2001, Journal of lipid research.

[19]  P. Durrington,et al.  Paraoxonase and Atherosclerosis , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[20]  D. Shih,et al.  Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[21]  Antonio F. Hernández,et al.  Hydrolysis of platelet-activating factor by human serum paraoxonase. , 2001, The Biochemical journal.

[22]  C Watson,et al.  Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[23]  P. Stetson,et al.  Rabbit Serum Paraoxonase 3 (PON3) Is a High Density Lipoprotein-associated Lactonase and Protects Low Density Lipoprotein against Oxidation* , 2000, The Journal of Biological Chemistry.

[24]  R. Angell,et al.  Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: an ideal plasma inactivation mechanism. , 2000, Journal of medicinal chemistry.

[25]  B. La Du,et al.  Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : apolipoprotein A-I stabilizes activity. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[26]  T. Standiford,et al.  On the physiological role(s) of the paraoxonases. , 1999, Chemico-biological interactions.

[27]  B. La Du,et al.  Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. , 1999, Free radical biology & medicine.

[28]  N. Weintraub,et al.  Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. , 1998, Circulation research.

[29]  M. Kobayashi,et al.  Lactone-ring-cleaving enzyme: genetic analysis, novel RNA editing, and evolutionary implications. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Fulton,et al.  A method for the determination of 5,6-EET using the lactone as an intermediate in the formation of the diol. , 1998, Journal of lipid research.

[31]  D. Shih,et al.  Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.

[32]  C. Kuo,et al.  Calcium binding by human and rabbit serum paraoxonases. Structural stability and enzymatic activity. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[33]  S. Scherer,et al.  Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. , 1998, Gene.

[34]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[35]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[36]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[37]  J. Berliner,et al.  Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. , 1995, The Journal of clinical investigation.

[38]  C. Kuo,et al.  Comparison of purified human and rabbit serum paraoxonases. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[39]  E. Greenberg,et al.  A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Humbert,et al.  Characterization of cDNA clones encoding rabbit and human serum paraoxonase: the mature protein retains its signal sequence. , 1991, Biochemistry.

[41]  P. Durrington,et al.  Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.

[42]  P. Schulam,et al.  Evidence for 5-lipoxygenase activity in human B cell lines. A possible role for arachidonic acid metabolites during B cell signal transduction. , 1990, Journal of immunology.

[43]  A. Motulsky,et al.  Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase. , 1989, Analytical biochemistry.

[44]  R. D. Dyer,et al.  Synthesis and 5‐Lipoxygenase Inhibitory Activity of 5‐Hydroperoxy‐ 6,8,11,14‐eicosatetraenoic Acid Analogues. , 1987 .

[45]  R. D. Dyer,et al.  Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8,11,13-tetraenoic acid analogues. , 1987, Journal of medicinal chemistry.

[46]  R. D. Dyer,et al.  Structural requirements for the inhibition of 5-lipoxygenase by 15-hydroxyeicosa-5,8,11,13-tetraenoic acid analogues. , 1987 .

[47]  A. Kreft,et al.  Inhibition of platelet and neutrophil phospholipase A2 by hydroxyeicosatetraenoic acids (HETES). A novel pharmacological mechanism for regulating free fatty acid release. , 1985, Biochemical pharmacology.

[48]  A. Kreft,et al.  Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages. , 1985, European journal of pharmacology.

[49]  B. La Du,et al.  The human serum paraoxonase/arylesterase polymorphism. , 1983, American journal of human genetics.

[50]  J. Bryan,et al.  Molecular weights of protein multimers from polyacrylamide gel electrophoresis. , 1977, Analytical biochemistry.

[51]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[52]  K. Ferguson,et al.  STARCH-GEL ELECTROPHORESIS--APPLICATION TO THE CLASSIFICATION OF PITUITARY PROTEINS AND POLYPEPTIDES. , 1964, Metabolism: clinical and experimental.

[53]  B. La Du,et al.  Pharmacogenetics of paraoxonases: a brief review , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[54]  D. Shih,et al.  CHD and Atherosclerosis: Human Epidemiological Studies and Transgenic Mouse Models , 2002 .

[55]  M. Mitchell,et al.  Lipoxygenase activity in human uterine and intrauterine tissues: new prospects for control of prostacyclin production in pre-eclampsia. , 1983, Clinical and experimental hypertension. Part B, Hypertension in pregnancy.